Clinical trials: Exercise Pulmonary Hypertension
Sickle Cell Anemia, Pulmonary Hypertension
Exercise-induced Pulmonary Hypertension in Patients With Sickle-cell Anemia
Pulmonary hypertension (PH) at rest is a risk factor for death in patients with sickle-cell anemia (SCA). Exercise echocardiography (EE) can detect latent PH.
- Trial name
- NCT00948012
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Exercise Tolerance, Dyspnea
Study of Exercise and Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease
Heart Failure with Preserved Ejection Fraction (HFpEF) and Pulmonary Hypertension (PH) can be diagnosed noninvasively by Exercise Echocardiography (ExE) and Cardiopulmonary Exercise Testing (CPX) as compared with gold standard…
- Conditions
- Exercise Tolerance, Dyspnea, Heart Failure, Pulmonary Hypertension
- Trial name
- EXEC (NCT01418248)
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
CPAP Therapy in Obstructive Sleep Apnea Patients With Pulmonary Hypertension
All patients are newly diagnosed Obstructive Sleep Apnea patients performing full night polysmnographic sleep study, whose echocardiographic findings elucidate presence of pulmonary hypertension(PH).
- Trial name
- NCT04769635
- Testing
- CPAP therapy
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Zagazig University
High Altitude, Healthy Adult
Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Healthy Adult, Echocardiography, Pulmonary Resistance
- Trial name
- NCT07804485
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito: 2850m) to sea level on six-minute walking distance and scores in patients with pulmonary arterial hypertension PAH, who live permanently >2600m.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, High Altitude Effects
- Trial name
- NCT07804472
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
High Altitude Effects, High Altitude
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in patients with pulmonary arterial…
- Conditions
- High Altitude Effects, High Altitude, Pulmonary Vascular Disease, Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07801859
- Testing
- Descent and re-ascent (2850m, sea level)
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Hypertension, Pulmonary
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
This study will collect information about physical activity in patients affected by pulmonary hypertension, through a specific device that can be worn on the wrist, and which measures daily step count.
- Trial name
- STEPinPH (NCT03043976)
- Testing
- Actigraph GT9X Link device
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College Healthcare NHS Trust
Pulmonary Hypertension
Acute Responses of Active Video Games and Traditional Exercise Program in in Patients With Pulmonary Hypertension
At least 20 volunteers with a diagnosis of Pulmonary Hypertension in the Department of Cardiology of Dokuz Eylul University and who meet the criteria for follow-up and inclusion will participate in the study.
- Trial name
- NCT05901168
- Testing
- Active Video Games Intervention, Traditional Exercise Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Dokuz Eylul University
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
- Trial name
- BETTER COPD-PH (NCT05937854)
- Testing
- Tadalafil
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- VA Office of Research and Development
Pulmonary Hypertension, Iron Deficiency
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
Pulmonary hypertension (PH) is a condition characterized by elevated blood pressure in the pulmonary arteries. This leads to symptoms such as shortness of breath and a significantly reduced exercise capacity, resulting in a very…
- Trial name
- IRON-PH (NCT07359599)
- Testing
- Ferric Carboxymaltose (FCM), Sodium Chloride (NaCl) 0.9 %
- Where
- 7 sites in Belgium
- Volunteers
- 306 people
- Sponsor
- Ziekenhuis Oost-Limburg
Pulmonary Arterial Hypertension
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
- Trial name
- NCT06409026
- Testing
- Sotatercept
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Blood and Tissue Oxygenation (aBGA, NIRS)
Randomized crossover trial in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary Hypertension (CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above…
- Trial name
- NCT03637114
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Mild Pulmonary Hypertension
A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]
The investigators hypothesized that udenafil, a newly developed phosphodiesterase type 5 inhibitor, would improve symptom, exercise capacity and hemodynamic status in patients with mild pulmonary hypertension.
- Trial name
- NCT01696240
- Testing
- Udenafil (Zydena)
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Pulmonary Hypertension
Telerehabilitation in Patients With Pulmonary Hypertension
Patients with pulmonary hypertension will be randomized into two groups. One group will receive telerehabilitation sessions including upper and lower extremity strengthening exercises and breathing exercises.
- Trial name
- NCT04683822
- Testing
- Telerehabilitation
- Volunteers
- 30 people
- Sponsor
- Marmara University
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Cognitive Function
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on cognitive functions.
- Trial name
- NCT03637127
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Systemic Sclerosis, Shortness of Breath
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis.
- Conditions
- Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
- Trial name
- NCT01051960
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles